In this part of our 5-part series, Gus Alva, MD highlights the importance of education and overcoming skepticism about MDMA-assisted therapy.

In this part of our 5-part series, Gus Alva, MD talks about MDMA's efficacy in controlled settings and addresses misconceptions.

In this part of our 5-part series, Gus Alva, MD discusses the unmet need in PTSD treatment and the potential of MDMA-assisted therapy.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

Primary and secondary pharmacokinetic parameters through day 75 were similar across treatment arms.

Ashley Benson, MD, discusses the most recent International Federation of Gynecology and Obstetrics (FIGO) statement on iron deficiency and anemia in women and girls.

Hematologists, a gastroenterologist, and an obstetrician-gynecologist discuss the common causes of iron deficiency seen in clinical practice.

These new data were announced by Aquestive Therapeutics and if approved, Anaphylm Sublingual Film could be the first orally-delivered, non-invasive severe allergy treatment.

These data highlighted new findings on the experiences of children aged 6 to 11 with uncontrolled type 2 asthma treated with dupilumab.

A study demonstrated a smartphone app provides comparable benefits to cognitive behavior or mindfulness-based therapy, widening the supply gap for mental health care.

New research suggests combined treatment with fecal microbiota transplant and anti-PD-1 inhibitors may help overcome immune checkpoint inhibitor resistance in gastrointestinal cancers.

A predictable, structured routine was shown to promote consistent treatment adherence among a cohort of patients with gout.

Patient factors trended towards an association with a higher risk of proliferative sickle cell retinopathy but did not reach statistical significance.

These new phase 3 findings from ARCADIA 1 and 2 highlight the effects of nemolizumab in combination with either topical corticosteroids or topical calcineurin inhibitors.

A study found the association between physical activity engagement and reduction in depression symptoms is moderated by pain.

Personalized text messages can boost physical activity in cardiac rehab patients, especially in early stages, but effectiveness varies by time and device, study finds.

Higher PROs, which were indicative of worse disease activity, were more likely to be reported in the spring and fall months.

Positive topline results from the phase 2 SPRING trial highlight CM-101’s anti-fibrotic, anti-inflammatory, and anti-cholestatic effects in primary sclerosing cholangitis.

Intravitreal dosing of sozinibercept up to 2 mg in combination with ranibizumab or aflibercept was well tolerated and supported ≥Q8W dosing intervals.

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

The expanded label includes use in patients with PFIC 12 months of age and older as well as a higher concentration formulation.

This meta-analysis was conducted to compare the efficacy and safety of lebrikizumab to other systemic treatments for patients with atopic dermatitis.

In an interview Adrian Quartel, MD, discusses the next steps for evaluating KP1077 in idiopathic hypersomnia after the phase 2 study.

The nomogram was constructed using independent risk factors for early cirrhosis and demonstrated greater diagnostic accuracy than current noninvasive fibrosis tests.

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.